In vitro activity of lomefloxacin against multiply resistant Pseudomonas aeruginosa, enterobacter cloacae, and Staphylococcus epidermidis

Lomefloxacin is a promising new difluorinated quinolone with good antimicrobial activity and favorable pharmacokinetic properties. The in vitro activity of lomefloxacin was compared to other quinolones, expanded spectrum β-lactams, and gentamicin. The lomefloxacin MIC 90 against multiply resistant s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diagnostic microbiology and infectious disease 1989-05, Vol.12 (3), p.13-16
Hauptverfasser:	DiVincenzo, Cathy A., Shatzer, Kari L., Venezio, Frank R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Infective Agents - pharmacology Ciprofloxacin - pharmacology Drug Resistance, Microbial Enterobacter - drug effects Enterobacteriaceae Fluoroquinolones Humans Microbial Sensitivity Tests Norfloxacin - pharmacology Pseudomonas aeruginosa - drug effects Quinolones Staphylococcal Infections - drug therapy Staphylococcus epidermidis - drug effects Staphylococcus epidermidis - isolation & purification
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Lomefloxacin is a promising new difluorinated quinolone with good antimicrobial activity and favorable pharmacokinetic properties. The in vitro activity of lomefloxacin was compared to other quinolones, expanded spectrum β-lactams, and gentamicin. The lomefloxacin MIC 90 against multiply resistant strains of P. aeruginosa was 4 mcg/ml, comparable to norfloxacin and ofloxacin. Lomefloxacin was also active against methicillin-resistant S. epidermidis and JK corynebacteria. The role of lomefloxacin in the treatment of infections caused by multiresistant organisms remains to be determined in clinical trials.
ISSN:	0732-8893 1879-0070
DOI:	10.1016/0732-8893(89)90059-X